Citations

Clear

4610 citation(s) found for "Lu, Brian".

Neurohospitalist Core Competencies
Wold, Jana , Robertson, Jetter , Jeevarajan, Jerome , Knox, Molly G., Thatikunta, Prateek , Solorzano, Guillermo E., Galetta, Kristin , Dujari, Shefali , Goyal, Tarini , Ehrlich, Matthew , Donnelly, J., Marriott, Elizabeth , Mandge, Vishal , Dhoot, Roshni , Luedke, Matthew W. , Maas, Matthew B., Yu, Mei , Tolédano, Michel B. , Palaganas, Jamie L., Kvam, Kathryn A. , Dugue, Rachelle , Meltzer, Ethan , Touma, Lahoud , Shah, Maulik , Douglas, Vanja C. , Orjuela, Karen , Klein, Joshua P. , Likosky, David, Simpson, Jennifer , Richie, Megan , Dohle, Carolin, Morris, Jane G. , Gold, Carl A. , Maas, Matthew B. , Wold, Jana J , Ehrlich, Matthew E , Mustafa, Rafid , Kvam, Kathryn , Meltzer, Ethan , Shah, Maulik P , Orjuela, Karen , Klein, Joshua P , Gold, Carl A , Yu, Margaret Y., Toledano, Michel, Mustafa, Rafid , Palaganas, Jamie, Scott, Brian J.

Mayo Clinic

The Neurohospitalist | November 26, 2024 | Volume: 15 | Issue: 1 | Pages: 13-84

10.1177/19418744241297187 | PMID 39610897 Get It

The Neurohospitalist Core Competencies comprise a set of competency-based learning objectives that encapsulate the knowledge, skills, and attitudes of neurohospitalitists who specialize in the care of hospitalized patients with neurologic conditions. These competencies serve to characterize the rapidly expanding field of neurohospitalist medicine. The 27 chapters are divided into 3 sections entitled: neurological conditions, clinical interventions and interpretation of ancillary studies, and neurohospitalist role in the healthcare system. Each individual learning objective in the chapters describes a specific concept with an action verb to illustrate the behavior that the neurohospitalist exhibits. The individual neurohospitalist may not exhibit mastery in each of the topics included as individual practices vary in scope and practice pattern. A few examples of how the complete set of competencies may be used include in the creation of curricula for neurohospitalist fellowships, to assist in defining the scope of practice of neurohospitalists for administrative leaders of hospitals and departments, and in influencing the direction of further research and quality improvement in the field.
Outcomes of Proximal Row Carpectomy With Interposition Arthroplasty for Advanced Wrist Arthritis
Adenikinju, Abidemi , Wu, Kitty Y. , Karim, Kristin, Carlsen, Brian T. , Kakar, Sanjeev , Carlsen, Brian, Kakar, Sanjeev , Karim, Kristin E.

Mayo Clinic

HAND | November 23, 2024 | Volume: 21 | Issue: 2 | Pages: 271-276

10.1177/15589447241298721 | PMID 39579002 Get It

Background: This study aimed to evaluate and compare the outcomes of proximal row carpectomy (PRC) with interposition arthroplasty using dorsal wrist capsule interposition, lateral meniscus allograft, or dermal allograft in patients with lunate facet/capitate degeneration. Methods: Patients who underwent PRC with interposition arthroplasty between 2010 and 2022 at a single institution were identified. Preoperative and postoperative visual analog scale (VAS) pain, functional outcomes, and complications were recorded. Results: Twenty-one patients (11 dorsal capsule, 6 meniscus, 4 dermal matrix) were identified with a mean follow-up of 65.8 months. Postoperative pain and functional outcome scores significantly improved. The mean postoperative Quick Disabilities of the Arm, Shoulder, and Hand score was 20.3. In total, 89.5% of patients returned to work, including 75% of manual laborers. Conclusions: No significant differences were found between dorsal capsular flap versus allograft groups. Proximal row carpectomy with interposition arthroplasty is an effective motion-sparing procedure for patients with proximal capitate and/or lunate fossa arthritis, improving pain and function.
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Mellinghoff, Ingo K. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Gordon, Gary, Lassman, Andrew B. , Lim, Michael , Perry, James , Wen, Patrick Y. , Yung, W.K. Alfred , Berry, Nicholas , Graves, Todd, Detry, Michelle A. , Hyddmark, Emma Maria Viktoria, Johnsson, Adam, Kling, Heather M., Powell, Ashley A., Untch, Sarah, Aquilanti, Elisa , Blondin, Nicholas, Boulmay, Brian C., Fuente, Macarena de la, Lobbous, Mina , Mikkelsen, Tom , Newton, Herbert B. , Schiff, David , Sherman, Wendy, Weathers, Shiao-Pei, Friend, John, Lee, E., Mellinghoff, Ingo K , Cloughesy, Timothy F. , Alexander, Brian M. , Cavenee, Webster K. , Colman, Howard , Groot, John de , Ellingson, Benjamin M. , Khasraw, Mustafa , Sulman, Erik P. , Weller, Michael , Wen, Patrick Yung , Johnsson, Adam, McGlothlin, Anna , Powell, Ashley, Drappatz, Jan , Jordan, Justin T. , Kaley, Thomas , Owen, Scott , Peters, Katherine B. , Schiff, David, Weathers, Shiao‐Pei , Youssef, Michael , Friend, John

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1302 Get It

Abstract GBM AGILE(NCT03970447) is a phase 2/3 Bayesian adaptive registration platform trial testing multiple therapies against a common control. Paxalisib, a PI3K/mTOR inhibitor, is the 3rd arm in the trial to conclude evaluation. METHODS Paxalisib was open to patients with newly diagnosed unmethylated (NDU) and recurrent (RD) glioblastoma, with three possible signatures: NDU, RD, and All(NDU+RD). Arm enrollment occurred Dec2020 through May2022. Control patients were enrolled from study initiation (July2019) and were treated with temozolomide(NDU) or lomustine(RD). GBM AGILE investigational arms have 1 or 2 stages, with adaptive randomization in stage 1 and fixed randomization if arms continue to stage 2. Efficacy is based on OS hazard ratio(HR) of Arm/Control. Efficacy goal is final Bayesian probability ≥ 98% for HR<1.00 in combined Stages. An Arm continues to Stage 2 if Bayesian predictive power (PP) ≥ 0.8. An Arm stops accruing in Stage 1 if it reaches maximal sample size(N) or does not meet a minimum efficacy threshold (PP<0.25 for all signatures when N>50). Clinical cut-off is 12 months after accrual stops. The maximum N for paxalisib was approximately 150(Stage 1) and 50(Stage 2). RESULTS After paxalisib reached >150 patients in Stage 1, accrual stopped [Paxalisib/control N 54/75(NDU), 100/188(RD)]. Neither PP thresholds for moving to Stage 2 nor stopping for minimum efficacy were met. Following an unplanned public disclosure that the arm did not continue to stage 2, clinical cut-off for final analysis (planned May2023) was updated to public disclosure date (August2022). At final analysis mean HRs were 0.89(NDU), 1.25(RD), 1.05(All), probabilities of HR<1.00 of 0.72(NDU), 0.076(RD), 0.398(All). Model estimated median OS paxalisib/control (months) were 14.77/13.84(NDU) and 8.58/10.06(RD). CONCLUSION Paxalisib did not show survival benefit over cumulative control in final primary analysis; additional secondary analyses are being considered. GBM AGILE continues to rapidly and efficiently assess therapies in ND and RD glioblastoma.
Intraoperative Electrical Stapedius Reflex Testing to Monitor Cochlear Nerve Integrity during Simultaneous Vestibular Schwannoma Resection and Cochlear Implantation
Carlson, Matthew L. , Daher, Ghazal S. , Khandalavala, Karl R. , Lohse, Christine M. , Neff, Brian A., Driscoll, Colin L. W., Peris-Celda, Maria, Link, Michael J. , Saoji, Aniket A. , Peris‐Celda, Maria , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | November 21, 2024 | Volume: 46 | Issue: 1 | Pages: 60-66

10.1097/mao.0000000000004379 | PMID 39666744 Get It

Objective To compare the utility of intraoperative electrically evoked auditory brainstem response (eABR) and electrically evoked stapedial reflex testing (eSRT) for cochlear nerve integrity monitoring during simultaneous translabyrinthine resection of vestibular schwannoma (VS) and cochlear implantation. Study design Historical cohort study. Setting Tertiary academic referral center. Patients Eleven patients (12 cases) who underwent translabyrinthine tumor resection with simultaneous placement of a standard, unmodified cochlear implant (CI). Intervention A CI placed at the beginning of the operation before tumor resection to facilitate intraoperative cochlear nerve monitoring through a CI-delivered electrical stimulus. Main outcome measure Correlation of intraoperative monitoring outcomes with postoperative CI performance. Results Among the 12 cases (median age, 47 years), eABR waveforms were present at the conclusion of tumor resection in 10, including 6 that achieved open set speech perception. Of the 2 cases with negative eABR, 1 achieved open set speech perception. By contrast, of the 8 cases with a positive eSRT response, 7 achieved open set speech perception. Of the 4 cases with a negative eSRT response, none achieved open set speech perception. The 3 cases that did not receive auditory stimulation included 2 with positive and 1 with negative eABR; all 3 had a negative eSRT response. Conclusions Intraoperative eSRT using an unmodified CI is a promising new method for monitoring the integrity of the cochlear nerve during simultaneous VS resection. eSRT response at the conclusion of tumor resection strongly correlated with CI open set speech capacity. Although still useful, eABR was less reliable at predicting postoperative hearing outcomes in this series.
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Mendez, Joe , Cohen, Adam L. , Eckenstein, Midori, Jensen, Randy L. , Burt, Lindsay , Salzman, Karen L. , Chamberlain, Marc C. , Hsu, Henry H. , Hutchinson, Marguerite, Mrugała, Maciej M. , Pelayo, Michael, Raizer, Jeffrey J. , Reardon, David A. , Sterba, Michael, Walbert, Tobias , Wong, Eric T. , Zhang, Chao , Colman, Howard , Mendez, Joe S , Reardon, David A , Walbert, Tobias , Colman, Howard , IWAMOTO, FABIO MASSAITI , Ligon, Keith L , Plotkin, Scott R. , Puduvalli, Vinay K. , West, Brian L.

Mayo Clinic

Neuro-Oncology Advances | November 19, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae202 | PMID 39734810 Get It

Abstract Background Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indicate that combining radiation therapy (RT) and pexidartinib reduces radiation resistance. We added pexidartinib to standard-of-care RT/temozolomide (TMZ) in patients with newly diagnosed GBM to assess the therapeutic benefit of altering the tumor microenvironment with pexidartinib. Methods In this open-label, dose-escalation, multicenter, Phase 1b/2 trial, pexidartinib was administered in combination with RT/TMZ followed by adjuvant pexidartinib + TMZ. During Phase 1b, pexidartinib was given 5 or 7 days/week at multiple dosing levels. The primary Phase 1b endpoint was the recommended Phase 2 dose (RP2D). Phase 2 patients received the RP2D with the primary endpoint of median progression-free survival (mPFS). Secondary objectives were median overall survival (mOS), pharmacokinetics, and safety. Results The RP2D of pexidartinib was 800 mg/day for 5 days/week during RT/TMZ, followed by 800 mg/day for 7 days/week with adjuvant TMZ. mPFS was 6.7 months (90% CI: 4.5, 11.5) for the modified intention-to-treat population. The actual mOS was 13.1 months (90% CI: 11.5, 24.5), and the mOS corrected for comparison with matched historical controls was 18.8 months (95% CI: 12.6, 28.0). Conclusions This trial established the RP2D of pexidartinib in combination with RT/TMZ and adjuvant TMZ. Pexidartinib was generally safe and well tolerated. Although the study regimen with pexidartinib was not efficacious, pharmacodynamic studies showed modulation of systemic markers that could lead to alteration of the tumor microenvironment.
Diagnosing and managing gastroparesis - where are we now?
Olson, Caroline G. , Lacy, Brian E. , Olson, Caroline

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | November 18, 2024 | Volume: 18 | Issue: 11 | Pages: 681-683

10.1080/17474124.2024.2431248 | PMID 39552392 Get It

Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?
Brunelli, Alessandro , Petersen, René Horsleben , Stiles, Brendon M. , Wigle, Dennis A. , Collaborators, Platz, Joseph , Muesse, Jason , Grenda, Tyler R., Makey, Ian A. , Khandhar, Sandeep J. , Schipper, Paul H., Linsky, Paul L., Liptay, Michael J, Pechet, Taine, White, Abby , Wood, Douglas E. , Brandt, Whitney S. , Martin, Linda D., Patterson, Alec, Seder, Christopher W. , Lanita, Michael, Molena, Daniela , Lee, Jay M. , Healy, David , Decker, G. Anton , Sihoe, Alan , Zairi, Sarra , Dunning, Joel , Raveglia, Federico , Kleontas, Athanasios, Szántó, Zalán , Nosotti, Mario , Hudson, Jessica , Schneiter, Didier, Asadi, Nizar , Aranda, J.M. Botía, Congregado, Miguel , Backhus, Leah, Bertani, Alessandro , Nadal, Sergio Bolufer, Rosso, Lorenzo, Gattás, Gustavo, Augustin, Florian , Milton, Richard , Vannucci, Fernando , Waller, David , Gasparri, Mario, Reddy, Rishindra M. , Schreurs, W. H. , Saftić, Igor, Scarci, Marco, Toker, Seyfi Alper, Welcker, K , Furák, József, Durand, Marion, Hugen, Niek , Joseph, Lula Lukadi, Chiappetta, Marco , Pérez, María Rodríguez, Minasyan, Anna , Filose, Pier Luigi, Elkhayat, Hussein , Wei, Benjamin , Leone, Richard J., Chang, Albert S., Curcio, Carlo, Sparks, Preston, Hagen, Jeffrey A., Baste, Jean Marc , Taylor, Lauren , Xavier, D'journo, Hall, David Jeffrey, Hansen, Henrik Jessen, Leschber, Gunda, Koryllos, Aris , Gandhi, Shilpa , Batgirl, Hasan, Calvin, Ng Sze Hang, Sotiropoulos, Georgios C. , Furrer, Markus , Danjouma, Cheufou, Novoa, Nuria , Cassivi, Stephen D. , Veronesi, Giulia , Hamouri, Shadi , Štupnik, Tomaž , Hall, David J. , Antonoff, Mara B. , Collaborators, Louie, Brian E. , Daddi, Niccolò , Swisher, Stephen G. , Yendamuri, Sai S , Liptay, Michael J, Herrera, Luis, Martin, Linda, Patterson, Alec, Sandri, Alberto , Ruffini, Enrico , Maurizi, Giulio , Kleontas, Athanasios, Depypere, Lieven , Caruana, Edward Joseph , Mitchell, John , Gonfiotti, Alessandro , Pagès, P , Aranda, Jose, Billè, Andrea , Falcoz, Pierre‐Emmanuel , Rosso, Lorenzo , Terra, Ricardo Mingarini , Raemdonck, Dirk Van , Minervini, Fabrizio , Tosi, Davide , Solli, Piergiorgio , Scarci, Marco , Gooseman, Michael , Gossot, Dominique , Álvarez, Antonio , Toker, Seyfi Alper, Aramini, Beatrice , Guerrera, Francesco , Jiménez, Marcelo Fernando , Bölükbas, Servet , Thomas, P. A. , Luzzi, Luca , Aigner, Clemens , Minasyan, Anna, Kim, Young Tae , Pompili, Cecilia , Shargall, Yaron , Fiorelli, Alfonso , Curcio, Carlo, Bilfinger, Thomas V. , Engelhardt, Kathryn Elizabeth , Hall, David Jeffrey, Akopov, Andrey L. , Loos, Erik Robert de , Karamustafaoğlu, Yekta Altemur , Bertolaccini, Luca , Hendriks, Jeroen M. , Scanagatta, Paolo , Prisciandaro, Elena , Gómez-Hernández, María Teresa , Agrafiotis, Apostolos C. , Casiraghi, Monica , Danjouma, Cheufou Housmanou, Mariani, Alessandro Wasum , Antonio, David Gómez de , Bolca, Ciprian Nicolae , Cattaneo, Margherita

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 15, 2024 | Volume: 66 | Issue: 5 | Pages: No page available

10.1093/ejcts/ezae344 | PMID 39545513 Get It

Abstract 4147050: Genetic Insights into Arrhythmogenic Mitral Valve Prolapse – A Case-Control Study from UK Biobank and NIH All of Us
Dabbagh, Ghaith Sharaf , Hesse, Kerrick , Agnihotri, Ruchi, Kaur, Gurpreet , Gurumoorthi, Manasa, Mitchell, Saige M. , Pargament, Robert, Malik, Adnan , Schuler, Brian, Obeng‐Gyimah, Edmond, Ricci, Fabrizio , Landstrom, Andrew P. , Landstrom, Andrew P , Agnihotri, Ruchi, Shah, Ravi V. , Asatryan, Babken , Galanti, Kristian , Wolfe, Rachel, Malik, Adnan, Munroe, Patricia B. , Somers, Virend K. , Ricci, Fabrizio , Khanji, Mohammed Y , Chahal, C. Anwar A.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147050 Get It

Background: Mitral valve prolapse (MVP) is a common valvular abnormality. Observational studies demonstrate an association between MVP and increased risk of sudden cardiac death from ventricular arrhythmias, coined arrhythmogenic MVP. A genetic component has been postulated but remains under-investigated. Hypothesis: Predicted deleterious variants in Mendelian cardiomyopathy and arrhythmia genes are more frequent in arrhythmogenic MVP (aMVP) compared to non-arrhythmogenic MVP. Aims: To comprehensively phenotype and genotype a single-center aMVP cohort and compare to non-aMVP from two large population-based cohorts and investigate their clinical outcomes. Methods: The aMVP cohort included 46 prospectively enrolled patients from a regional referral center for inherited cardiovascular disease and had undergone multi-modality imaging and clinical gene panel testing. The non-aMVP comparator cohorts included 453 participants from the UK Biobank (UKBB), a prospective cohort of 500,000 UK residents, and 1,418 participants from the National Institutes of Health (NIH) All of Us (AoU), a prospective cohort of 450,000 USA participants. Gene variants were annotated in ANNOVAR. Participants with and without pathogenic/likely pathogenic (P/LP) variants reported on ClinVar with ≥2-star level of evidence were considered genotype positive (G+) and negative (G-) respectively. Results: The demographics for aMVP (age 61.2 ± 12.8 years, 56.5% female) and non-aMVP (UKBB: age 59.8 ± 7.3 years, 50.7% female and AoU: age 65.3 ± 13.4 years, 76.2% female) were comparable. G+ participants were more prevalent in the aMVP cohort 10/46 (21.7%) versus non-aMVP in the UKBB 8/453 (1.8%) and in the AoU 21/1418 (1.5%); p<0.001. The most frequently implicated gene in aMVP was TTN . Of 46 in aMVP cohort, 33 (71%) underwent CMR. G+ participants had a higher frequency of late gadolinium enhancement [6/6 (100%) vs. 14/27 (51.8%), p<0.001] and wall motion abnormalities [3/6 (50%) vs. 1/27 (3.7%), p<0.001] compared to G- participants. The aMVP cohort had significantly more implantable cardioverter defibrillator (ICD) implants compared to non-aMVP cohort [5/46 (10.9%) vs. 1/453 in UKBB (0.2%), p<0.001]. G+ aMVP cohort showed a trend for developing heart failure and ICD implants compared to G- aMVP . Conclusion: P/LP variants in cardiomyopathy and arrhythmia genes are more prevalent in aMVP participants compared to non-aMVP participants. This could be a hitherto unrecognized effect modifier predicting aMVP .
A Novel Machine Learning Model to Predict Revision ACL Reconstruction Failure in the MARS Cohort
Group, MARS, Vasavada, Vrinda, Devana, Sai K. , Hame, Sharon L. , Jazrawi, Laith M. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Amendola, Annunziato, Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M., Creighton, R. Alexander , Dunn, Warren R. , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hannafin, Jo A., Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., Wright, Rick W. , York, James J. , Group, MARS, Vasavada, Kinjal , Moran, Jay T. , Lee, Chang Hee , Sherman, Orrin H. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Brophy, Robert H. , Cox, Charles L. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Spang, Jeffrey T. , Vidal, Armando F. , Williams, James S. , Wolf, Brian R.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 14, 2024 | Volume: 12 | Issue: 11 | Pages: No page available

10.1177/23259671241291920 | PMID 39555321 Get It

Background: As machine learning becomes increasingly utilized in orthopaedic clinical research, the application of machine learning methodology to cohort data from the Multicenter ACL Revision Study (MARS) presents a valuable opportunity to translate data into patient-specific insights. Purpose: To apply novel machine learning methodology to MARS cohort data to determine a predictive model of revision anterior cruciate ligament reconstruction (rACLR) graft failure and features most predictive of failure. Study Design: Cohort study; Level of evidence, 3. Methods: The authors prospectively recruited patients undergoing rACLR from the MARS cohort and obtained preoperative radiographs, surgeon-reported intraoperative findings, and 2- and 6-year follow-up data on patient-reported outcomes, additional surgeries, and graft failure. Machine learning models including logistic regression (LR), XGBoost, gradient boosting (GB), random forest (RF), and a validated ensemble algorithm (AutoPrognosis) were built to predict graft failure by 6 years postoperatively. Validated performance metrics and feature importance measures were used to evaluate model performance. Results: The cohort included 960 patients who completed 6-year follow-up, with 5.7% (n = 55) experiencing graft failure. AutoPrognosis demonstrated the highest discriminative power (model area under the receiver operating characteristic curve: AutoPrognosis, 0.703; RF, 0.618; GB, 0.660; XGBoost, 0.680; LR, 0.592), with well-calibrated scores (model Brier score: AutoPrognosis, 0.053; RF, 0.054; GB, 0.057; XGBoost, 0.058; LR, 0.111). The most important features for AutoPrognosis model performance were prior compromised femoral and tibial tunnels (placement and size) and allograft graft type used in current rACLR. Conclusion: The present study demonstrated the ability of the novel AutoPrognosis machine learning model to best predict the risk of graft failure in patients undergoing rACLR at 6 years postoperatively with moderate predictive ability. Femoral and tibial tunnel size and position in prior ACLR and allograft use in current rACLR were all risk factors for rACLR failure in the context of the AutoPrognosis model. This study describes a unique model that can be externally validated with larger data sets and contribute toward the creation of a robust rACLR bedside risk calculator in future studies. Registration: NCT00625885 (ClinicalTrials.gov identifier).
Abstract 4139651: Cardiac Rehabilitation Following Thoracic Aortic Dissection Surgery: A Multi-Center Retrospective Study
Heybati, Kiyan , Ochal, Domenic, Poudel, Keshav , Zuberi, Eric , Tayon, Kevin , Farres, Sam, Landolfo, Kevin, Shapiro, Brian P. , Dineen, Elizabeth H. , Taylor, Bryan J. , Landolfo, Kevin

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4139651 Get It

Background: Despite expert opinion recommending patient-tailored cardiac rehabilitation (CR) after acute aortic dissection, both patient participation in CR and the associated risk factor modification after CR following aortic dissection repair are poorly understood. Objectives: To describe the characteristics of patients referred to CR, as well as the enrollment rate and outcomes of those referred to CR following thoracic aortic dissection. Methods: We reviewed electronic health records of adults (≥18) discharged alive following thoracic aortic dissection surgery across the Mayo Clinic Enterprise (01/01/2020-11/15/2022) with follow-up to 05/15/2024 (IRB #24-001141). Data are presented using summary statistics. Results: During the study period, 85 patients were included (median [IQR] age: 65 [50-75] years; 40% female; Table 1 ). Across 84% (N=71) who were referred to CR at discharge, 55% (N=39) enrolled. In those patients referred versus not referred to CR, the prevalence of type A dissection (75% vs. 43%), end-organ involvement (27% vs. 0%), and underlying CAD (54% vs. 21%) were greater while current tobacco use (9% vs. 29%) was lower. Of those enrolled at Mayo Clinic (N=16), CR was started 35 (28-65) days following surgery. These patients completed 21 (13-30) CR sessions at an exercise intensity of 59% (50-65%) maximum predicted heart rate. CR was discontinued in 44% (N=7) due to non-cardiac reasons ( Table 2 ). Of the 9 patients who completed CR, general health status (Dartmouth index: 19 [17-21] vs. 26 [22-34]), depressive symptoms (PHQ-9: 1 [0-1] vs. 4 [1-4]), and exercise capacity (6MWT: 214 [196-244] vs. 384 [305-597] meters) improved ( Table 2 ). There were no reported complications or deaths, with stable aortic sizes reported at 18 months. Conclusions: CR improves functional capacity and well-being without complications in patients after thoracic aortic dissection surgery. Further investigation is needed to better assess CR efficacy and usage in this population.